The British Society of Gastroenterology Audit on ERCP Availability Quality and Outcomes.

PROFORMA 3: PROCEDURE QUESTIONNAIRE



PROFORMA SHOULD BE COMPLETED FOR:

All patients age 18 or over attending for ERCP

ERCP defined as any procedure where an endoscope is inserted with the intention of cannulating the pancreatic duct, bile duct or both. Patients listed for stent removal without attempted cannulation need not be included.

QUERIES AND COMPLETED FORMS SHOULD BE ADDRESSED TO Dr. Earl Williams, Research Fellow, Dept. of Clinical Information, 4th Floor Linda McCartney Building, Royal Liverpool University Hospital, Prescot St., L7 8XP.

Tel 0151 7063794, Fax 0151 7062313 Email Earl.Williams@rlbuht.nhs.uk

THANKYOU

The British Society of Gastroenterology Audit on ERCP

PROFORMA 3: Procedure questionnaire - to be completed at time of ERCP

Instructions

- 1.Inclusion criteria: ALL patients age 18 or over attending for ERCP
- 2.ERCP defined as any procedure where an endoscope is inserted with the intention of cannulating the pancreatic duct, bile duct or both. Patients listed for stent removal without attempted cannulation need not be included.
- 3. Note in emergency cases where patient too sick to consent prior to procedure consent will need to be obtained retrospectively before forwarding a questionnaire to Liverpool. Where patient is indefinitely incapable of consenting exclude.
- 4. Endoscopist should answer questions in Section 1
- 5. Where a patient experiences an adverse event during procedure or immediate recovery period section 2 should be completed by endoscopist performing procedure. In this context an adverse event is defined as a detrimental deviation from the patient's expected clinical course occurring at ERCP or shortly (<4hours) afterwards. Where an adverse event occurs>4 hours after ERCP or proforma 3 is unavailable to reporting doctor use proforma 4 to record details. Where an adverse event is recorded the chief investigator will contact unit at 30 days to establish outcome.
- 6.To answer a question place a cross in one box only using black pen. i.e. \boxtimes If a question is labelled multiple response you may cross as many boxes as appropriate. Where a number or text is required print your response, keeping within the squares, if present. You do not need to prefix numbers with zero i.e. answer 3 rather than 003.
- 7. If you make a mistake block the box out entirely (and if necessary write correct text or number adjacent to box)

QUERIES AND COMPLETED FORMS SHOULD BE ADDRESSED TO Dr. Earl Williams, Research Fellow, Dept. of Clinical Information, 4th Floor Linda McCartney Building, Royal Liverpool University Hospital, Prescot St, L7 8XP. Tel 0151 7063794, Fax 0151 7062313 Email Earl.Williams@rlbuht.nhs.uk



SECTION 1: TO BE COMPLETED BY ENDOSCOPIST

Section 1

Proforma 3 v3.0 30/10/03

IDENTIFYING CODES - IMPORTANT,PLEASE COMPLETE FULLY	DRUGS AND MONITORING
IMPORTANT, I LEASE COURTED TO THE	4. Was General Anaesthesia Used?
1 Hospital Code	□ No Go to question 5
1. Hospital Code	Yes. Specify Reason:
Date of ERCP / / /	Now Go to question 7
Patient's Hospital Number Patients Date	5. During procedure: (multiple response) □ pulse oximetry was used □ automated BP monitoring was used
Of Birth /	☐ ECG monitoring was used 6.Indicate medication given during
	ERCP: (multiple response)
	Routinely Used Drugs Total Dose by end of ERCP
	☐ Midazolam
2.For each endoscopist involved in the procedure insert their code against the description that best describes their	☐ Diazepam ☐ mg
role.If you don't know an endoscopist's code ring 0151 706 3794 or speak to your consultant lead	□ pethidine □ □ mg
Code Role during Endoscopy	☐ fentanyl ☐ ☐ mcg
Independent (ie performed procedure without	□ propofol mg
other endoscopist present to advise or assist)	□ nalbuphane (nubaine) mg
Not independent (ie. other endoscopist in room to provide advice or assistance)	□ buscopan mg
100m to provide advice of dissimilarity	GTN mg
Supervising (i.e present to provide advice or assistance to trainee/other endoscopist.) Indicate	☐ lignocaine spray
level of help you gave during this ERCP	oxygen
(multiple response)	Antibiotic (If Used)
☐ Verbal instruction	☐ Antibiotics according to unit protocol
☐ assisted or performed cannulation (include precut) ☐ assisted or performed post	☐ Antibiotics (individualised regimen)
cannulation procedures	Reversal Agents/Additional Drugs Required
☐ No help required by other endoscopist/trainee	☐ flumazenil mcg
LOCATION	naloxone mcg
3.The ERCP was performed in	☐ glucagon ☐ ☐ mg
☐ XRay ☐ Theatres	□ atropine □. □ mg
☐ Endoscopy ☐ Other Imaging suite	Other, specify: mg/mcg



PATIENT INFORMATION

7. Was the patient admitted as a daycase ie. in absence of adverse event expected to go home within 24 hours of arrival? yes no	11.Indicate if the patient's medical history includes (multiple response) Cirrhosis, definite or suspected
8. What was the degree of urgency?	☐ Ongoing haemodialysis
☐ Elective (at time to suit both clinician and patient) ☐ Scheduled (early ERCP but not immediately life saving) ☐ Urgent (as soon as possible after resuscitation)	Currently obese (BMI>30 - see definitions)
☐ Emergency (immediate ERCP with simultaneous resuscitation)	12.Indicate if the patient's surgical history includes (multiple response)
	☐ Previous Cholecystectomy
9. What was the ASA Grading of patient immediately prior to ERCP?	□ Previous Bilroth II
☐ Class I. Healthy patient with localised pathology requiring ERCP	□ Whipples or Roux en Y procedure
Class II. Mild systemic disease e.g. non limiting heart disease, controlled diabetes, hypertension, obesity	13.The patient's ERCP was
Class III. Severe systemic disease. Definite functional limitation e.g. Brittle diabetic, frequent angina, MI>3 months ago	☐ Their 1st ERCP Go To question 15 A repeat procedure planned at the time of their last ERCP
Class IV. Severe systemic disease with acute/unstable symptoms e.g. MI within last 3/12,organ failure,uncontrolled asthma	A repeat procedure unplanned at the time of their last ERCP
☐ Class V. Moribund. Submitted to	14.Indicate if the patient has history of (multiple response)
therapy as act of desperation	☐ Post ERCP pancreatitis
	☐ Previous biliary sphincterotomy
10. Indicate if the patient has been on any of the following medication in the last 3 days (multiple response)	☐ ERCP performed in the last 3/12
☐ Oral anticoagulant	15. Indicate if todays ERCP (multiple response)
☐ NSAID (include aspirin=>300mg per day)	☐ Involved a combined percutaneous/endoscopic approach
☐ Heparin (any form or dose)	☐ Is part of extracorporeal shock wave lithotripsy treatmen
☐ Antiplatelet treatment (include aspirin<300mg/day)	



PRIOR INVESTIGATION AND INDICATION

16. What symptoms/findings l investigation of the patien	nave prom t (multiple	pted further e response):	18.If you have indicated that the patient has had an abnormal USS, does the report identify:
☐ Jaundice	•	-	☐ Dilated common bile duct
☐ Abdominal Pain			multiple ☐ Intraductal stone(s) response
☐ Fever/Signs of sepsis			☐ A pancreatic mass
☐ Weight Loss			☐ Other abnormality, specify
☐ Abdominal Mass			
☐ Abnormal LFTs			19. If the patient has had blood tests in the last 7 days
☐ Abnormal Radiology			document the most recent available results (multiple entry)
☐ Other, specify			PTs Albuming/ L
17.Indicate the results of any the patient has had in the patient has had a test dupl months then report the recent (multiple response)	last 3 mon licated in sult of the	ths. If the the last 3	INR Bilirubin mM WCC 000 per mm3 Creatinine mcM
	Normal	Abnormal	20. What was your suspected diagnosis <u>BEFORE</u> ERCP was performed (multiple response)
Trans-Abdominal			☐ Intra ductal stones
Ultrasound (USS)	Ц	Ц	☐ Sphincter of Oddi Dysfunction/Functional pain
Computed			☐ Acute Cholangitis - Unresolved at time of ERCP
Tomography		Ш	☐ Acute Cholangitis - Resolved by time of ERCP
Magnetic Resonance			☐ Malignancy-Unspecified
Cholangio- Pancreatography			☐ Carcinoma of Pancreas
Endoscopic			☐ Cholangiocarcinoma ☐ Acute Pancreatitis - Unresolved at time of ERCP
Ultrasound			☐ Acute Pancreatitis - Resolved by time of ERCP
Percutaneous			Chronic Pancreatitis
Trans-hepatic Cholangiography			☐ Benign Extra-Hepatic Stricture
Chotangrogi apny			☐ Biliary Leak
Intra-Operative			☐ Primary Sclerosing Cholangitis
Cholangiography			☐ Stent dysfunction
			☐ Unknown
			☐ Other, Specify



PRE-PROCEDURE INTENT AND CANNULATION

	co IV di un discolo
21. Which ducts did you intend to cannulate <u>BEFORE</u> starting the ERCP	23. Was the ampulla successfully visualised?
Common Bile Duct (ie. cholangiogram via main papilla)	☐ Yes
☐ Main Pancreatic Duct (ie. pancreatogram via main papilla)	☐ No,unable to intubate oesophagus if No go to
☐ Accessory Duct (ie. pancreatogram via minor papilla)	□ No, pyloric stenosis present - question 34,page 7
	No, specify other reason if identified
22. <u>BEFORE</u> starting the ERCP did you expect to perform any of the following procedures? (multiple response)	
any of the following procedures: (maisper response)	
A. STENT REMOVAL	
☐ Remove Biliary Stent currently insitu	24.What was the ampullary appearance?
B. SPHINCTEROTOMY	│
☐ Biliary Sphincterotomy	☐ Patulous/Gaping
☐ Pancreatic Sphincterotomy	Bulging
C. STONE EXTRACTION	Dunging
☐ Common Bile Duct Stone Extraction	☐ Within or on edge of diverticulum
☐ Intrahepatic Duct Stone Extraction	Adjacent to diverticulum
☐ Pancreatic Duct Stone Extraction	☐ Other, specify
D. <u>STENT INSERTION</u>	
☐ Common Bile Duct Stent Insertion	
☐ Hilar/Intrahepatic Bile Duct Stent Insertion	25. What were the total number of cannulations /
☐ Pancreatic Duct Stent Insertion	cannulation attempts during procedure (Defined
E. BALLOON DILATATION	as each episode of contact with major or minor papillae by any endoscopist using any device and
☐ Balloon Dilatation of papilla	including each recannulation but excluding over
☐ Balloon Dilatation of CBD	the wire exchanges)
☐ Intra-Hepatic Biliary Duct Dilatation	
☐ Pancreatic Duct Dilatation	
F. DRAIN INSERTION	26. Was a PRECUT papillotomy required?
□ Nasobiliary Drainage	☐ Yes ☐ No
☐ Nasopancreatic Drainage	
G. HISTOLOGY, CYTOLOGY AND SAMPLING	27. Was there visible intramucosal injection during
☐ Biopsy (of ampulla or duct)	ERCP?
☐ Brush Cytology of Bile Duct	□ yes □ no
☐ Brush Cytology of Pancreatic Duct	
☐ Sampling	AD Y II. A Add - Longftimes continued (of any
H. SPHINCTER OF ODDI MANOMETRY Manometry	28 .Indicate total number of times contrast (of any volume) injected into the pancreatic duct during ERCP
L <u>OTHER PROCEDURES</u>	
☐ Other specify	
	1.1



FINDINGS AND POST-CANNULATION INTENT

29. INDICATE WHICH DUCTS WERE CANNULATED AND SUBSEQUENT FINDING:	31.Specify what your intent was <u>FOLLOWING</u>	
□ No ducts cannulated - Go To Question 33 (page 7)	<u>CANNULATION</u> (multiple response)	
□ Common Bile duct cannulated -	A. STENT REMOVAL	
specify cholangiogram findings: (Multiple response)	☐ Remove Biliary Stent currently insitu	
☐ Insufficient cannulation or contrast injected		
□ Normal	B. <u>SPHINCTEROTOMY</u>	
☐ Dilated common bile duct (>10mm corrected for magnification)	☐ Biliary Sphincterotomy	
☐ Bile duct leak	☐ Pancreatic Sphincterotomy	
☐ Suspected sclerosing cholangitis	C. STONE EXTRACTION	
☐ Stones within gall bladder	☐ Common Bile Duct Stone Extraction	
☐ Probable or definite bile duct stones, specify location and size:	☐ Intrahepatic Duct Stone Extraction	
Location(s) ☐ extrahepatic ☐ intrahepatic ☐ cystic duct Size ☐ largest<1cm ☐ largest>=1cm	Pancreatic Duct stone extraction	
Number □ <3 □ >=3	D. STENT INSERTION	
☐ Probable or definite bile duct stricture(s), specify location/type:	☐ Common Bile Duct Stent Insertion	
Location(s) ☐ distal to hilum ☐ hilum or above ☐ both	☐ Hilar/Intrahepatic Bile Duct Stent Insertion	
Type: ☐ Benign ☐ Malignant ☐ Indeterminate	☐ Pancreatic Duct Stent Insertion	
☐ Other, specify:	E. BALLOON DILATATION	
	☐ Balloon Dilatation of Papilla	
	☐ Balloon Dilatation of CBD	
☐ Pancreatic duct and/or ☐ Accessory duct cannulated -	☐ Intra-Hepatic Biliary Duct Dilatation	
specify pancreatogram findings: (Multiple response) □ Normal	☐ Pancreatic Duct Dilatation	
☐ Insufficient cannulation or contrast injected	F. DRAIN INSERTION	
☐ Pancreatic divisum	□ Nasobiliary Drainage	
☐ Probable or definite stones	☐ Nasopancreatic Drainage	
☐ Dilated (corrected diameter>6mm within head or >3mm within tail)		
☐ Acinirization (ie.blush of pancreatic parenchymal contrast)	G. HISTOLOGY, CYTOLOGY AND SAMPLING	
☐ Definite chronic pancreatitis (Cambridge criteria-see definitions):	☐ Biopsy (of ampulla or duct)	
☐ Main duct irregularity/dilatation ☐ >3 side branches abnormal	☐ Brush Cytology of Bile Duct	
☐ Probable or definite stricture, specify type:	☐ Brush Cytology of Pancreatic Duct	
☐ Malignant ☐ Benign ☐ Indeterminate	☐ Sampling	
Other, specify:	H. SPHINCTER OF ODDI MANOMETRY	
	☐ Manometry	
30. In light of cholangiogram/pancreatogram/ampullary findings:	I. <u>OTHER PROCEDURES</u>	
☐ I intended to perform procedures as listed in question 22—Go To Q 32	☐ Other specify	
☐ No further procedure was required as part of this ERCP-Go To Q 33,page 7		
My intent as indicated in question 22 was altered		



ATTEMPTED PROCEDURES AND OUTCOME

	appropriate. List all attempted procedures and also indicate if attempted procedure was completed according to definitions given in each box. If no procedures were attempted go straight to question 33 on page 7
	32A. STENT REMOVAL
	Stent removal attempted
	☐ Stent removal <u>completed</u> *
	*DEFINITION OF COMPLETED: stent removed from biliary tree/pancreatic duct
	32B. SPHINCTEROTOMY
	Type(s) attempted
	☐ Bile Duct Sphincterotomy
l	☐ Pancreatic Duct Sphincterotomy
	Indicate type of current setting Pure cutting current throughout
	☐ Blended current for all or part of procedure(s) ☐ ERBE/Endocut device used
	Indicate if length of (the externally visible) cut was <a>5mm for the
	☐ Bile Duct Sphincterotomy
	☐ Pancreatic Duct Sphincterotomy
	Indicate if sphincterotome introduced over wire (ie. wire guided procedure) for the
	☐ Bile Duct Sphincterotomy
	☐ Pancreatic Duct Sphincterotomy
	Indicate if Visible bleeding at end of procedure was <u>>5mls</u> as a result of the
	☐ Bile Duct Sphincterotomy
	☐ Pancreatic Duct Sphincterotomy
	Of sphincterotomies attempted the following were completed*
	☐ Bile Duct Sphincterotomy
	☐ Pancreatic Duct Sphincterotomy
	*DEFINITION OF COMPLETED: Where subsequent procedures requiring access to duct (eg stent insertion/stone extraction) were attempted these were also completed. Where no subsequent procedures were attempted operator judges whether sphincerotomy successfully completed or not.

32C. STONE EXT	<u>TRACTION</u>
<u>Attempted</u> stone e ☐ Common Bile D	extraction from the: uct
☐ Intra-Hepatic Du	acts
☐ Pancreatic Duct	
Devices used duri ☐ Balloon	ng attempted stone extraction
□ Basket	
☐ Mechanical lithe	otripsy
☐ Other, specify	
Attempted extra	action completed* from the
☐ Common Bile D	ouct
☐ Intra-Hepatic D	ucts
☐ Pancreatic Duct	
	OF COMPLETED:Duct spected stones (no residual stones)
32D. STENT INS	YEDTYAN
JDD: DIRITE	SERTION
	re placement was <u>attempted</u>
Location(s) when	re placement was <u>attempted</u> Duct
Location(s) when	re placement was <u>attempted</u> Duct patic Duct
Location(s) when Common Bile D Hilum/Intra He	re placement was <u>attempted</u> Ouct patic Duct : re attempts were <u>completed</u> *
Location(s) when Common Bile I Hilum/Intra He	re placement was <u>attempted</u> Duct patic Duct re attempts were <u>completed</u> *
Location(s) when Common Bile I Hilum/Intra He Pancreatic Duct Location(s) when Common Bile I	re placement was attempted Duct patic Duct re attempts were completed* Duct patic Duct
Location(s) when Common Bile D Hilum/Intra He Pancreatic Duct Location(s) when Common Bile D Hilum/Intra He Pancreatic Duct	re placement was attempted Duct patic Duct re attempts were completed* Duct patic Duct t in situ at end of procedure ail plastic straight metal
Location(s) when Common Bile I Hilum/Intra He Pancreatic Duct Location(s) when Common Bile I Hilum/Intra He Pancreatic Duct Type(s) of Stent 1. plastic pigt length (cm)	re placement was attempted Duct patic Duct re attempts were completed* Duct patic Duct t in situ at end of procedure ail plastic straight metal



ATTEMPTED PROCEDURES AND OUTCOME

	The state of the s
32E. <u>BALLOON DILATATION</u>	32H. <u>SPHINCTER OF ODDI MANOMETRY</u>
Dilatation <u>attempted</u> in the following location(s) ☐ At papilla	Manometry <u>attempted</u>
☐ Within common bile duct	Where attempted manometry completed*
☐ Within intrahepatic ducts	
☐ Within Pancreatic Duct	*DEFINITIONOF COMPLETED: trace assists in diagnosis
Attempted dilatation <u>completed*</u> in the following location(s) ☐ At papilla	321. OTHER PROCEDURES
☐ Within common bile duct	Attempted
☐ Within intrahepatic ducts	
☐ Within Pancreatic Duct	Indicate if you judged procedure successfully completed
*DEFINITIONOF COMPLETED: able to	Specify
insert balloon across selected stricture and inflate	procedure:
	OUTCOME
32F. <u>DRAIN INSERTION</u>	33. Total volume of
Insertion of following <u>attempted</u> ☐ Nasobiliary drain	contrast injected by end of ERCP
☐ Nasopancreatic drain	
-	34. At start of ERCP was there complete biliary obstruction
Attempted insertion of the following completed*	□ No
☐ Nasobiliary drain	☐ Yes If yes was this obstruction relieved: ☐ no
☐ Nasopancreatic drain	□ yes
*DEFINITIONOF COMPLETED: Drain inserted with distal tip above any obstructing lesion /stone	
	35 .Did the patient experience any adverse event during ERCP
22C HICKOLOGY OVERALOGY AND CAMPLING	
32G. HISTOLOGY, CYTOLOGY AND SAMPLING	Yes Fill in section 2 (NEXT PAGE)
Following attempted	□ No USE QUESTION 36 TO ENTER ANY FURTHER COMMENTS YOU FEEL ARE
☐ Biopsy (of ampulla or duct)	NECESSARY AND FORWARD COMPLETED FORM TO ADDRESS ON
☐ Brush cytology of bile duct	PAGE 1
☐ Brush cytology of pancreatic duct	36. PLEASE USE THIS SPACE IF YOU NEED TO
☐ Sampling	CLARIFY A RESPONSE
Of those attempted following <u>completed</u> * ☐ Biopsy (of ampulla or duct)	
☐ Brush cytology of bile duct	
☐ Brush cytology of pancreatic duct	
□ Sampling	
*DEFINITION OF COMPLETED:operator judges adequate specimens taken	



SECTION 2: TO BE COMPLETED IF ADVERSE EVENT NOTED IN ENDOSCOPY ROOM OR RECOVERY

	The state of the s
1.Onset of symptoms/signs (of adverse event) relative to ERCP	<pre>e.Indicate if as a result of adverse event(s):</pre>
☐ Pre-procedure (from starting preparation)	☐ ERCP was not started
☐ During Procedure (in endoscopy room)	☐ ERCP was stopped prematurely
☐ Early recovery (<4 hours after ERCP)	
2.Nature of adverse event (for each section a-g you may cross more than one box)	f.Change in aftercare as result of event(s): ☐ None
a.Events relating to medication given at time of procedure and sufficient to alter aftercare or require specific treatment:	☐ Extra consultation eg in outpatient or endoscopy recovery ☐ Planned discharge cancelled - patient to stay in
Generalised allergic reaction (rash +/- any of below)	☐ Extra treatment required in pre-existing inpatient
☐ Wheezing	☐ Admission to ITU
□ Нурохіа	g. Medical interventions received or planned at time of writing as result of event(s):
☐ Hypertension	☐ Reversal agents (flumazenil or naloxone)
☐ Hypotension	☐ Atropine
☐ Neuropsychiatric reaction	☐ Oxygen ☐ Transfusion <5 units
☐ Reaction at IV Site	☐ Transfusion> or equal to 5units
	☐ Ventilatory assistance eg bag and mask
b. Recognized Local Complications of ERCP, sufficient to alter aftercare or require specific treatment:	☐ Tracheal intubation ☐ Crash call
☐ Perforation, suspected or definite	h.Other(invasive) interventions received or planned at time
☐ GI bleeding	of writing as result of event(s):
☐ Basket impaction	Endoscopic
☐ Other Equipment failure or malfunction, specify:	Radiological/Percutaneous
	Surgery
	Other
c.Other events following ERCP sufficient to alter aftercare or require specific treatment:	
☐ Abdominal pain of uncertain origin	3. Outcome at time of writing (cross one box): ☐ Unknown as yet
☐ Chest pain of uncertain origin	☐ Full recovery
☐ Unstable coronary syndrome/Myocardial infarct	☐ Permanent disability/loss of function expected
☐ Cardiac arrythmia	□ Death
☐ Cerebro-Vascular Accident/Stroke	Date // // //
d. Other event or diagnosis that altered aftercare or required specific treatment	Cause of death Ib
	Π

DEFINITIONS

Complications - Definitions for questionnaire (Cotton, Lehman et al. 1991), (Cotton 1994)

Complication	Mild	Moderate	Severe	Fatal
Bleeding	Clinical (not just endoscopic) evidence of bleeding; HB drop <3g; no transfusion	Transfusion (4U or less), no angiographic or surgical intervention	Transfusion (5U or more) or intervention (angiographic or surgical)	Results in death
Perforation	Possible or slight leak of contrast; treated by fluids & suction for 3 days or less	Any definite perforation treated medically for 4-10 days	Hospitalisation for >10 days or any intervention (percutaneous or surgical).	Results in death
Pancreatitis (Abdo pain + amylase >3N after 24 hrs)	requiring admission or prolongation of planned admission beyond 48 hrs	requiring of 4-10 days hospitalisation	admission > 10 days; haemorrhagic pancreatitis; pseudocyst, intervention required	Results in death
Infection (cholangitis)	>38 °C 24-48 hrs	Febrile or septic illness requiring >3 days hospitalisation or endoscopic/percutaneou s intervention	Septic shock or surgery	Results in death
Miscellaneous (include symptomatic IHD, aspiration pneumonia, drug reactions)	Onset of relevant symptoms within 3days of ERCP. Requires 1-3 days hospitalisation/ prolongation of stay	Onset of relevant symptoms within 3 days of ERCP. Requires 4-10 days hospitalisation	Onset of relevant symptom within 3 days of ERCP. Requires >10days hospitalisation or ITU or surgical/radiological intervention	Results in death

Chronic Pancreatitis: Cambridge Classification

Terminology	Main duct	Abnormal side branches	Additional features
normal	normal	none	
equivocal	normal	<3	
mild	normal	3 or more	
moderate	abnormal	>3	
marked	abnormal	>3	One or more of: large cavity; obstruction; filling defects; severe dilatation or irregularity

Chart Depicting body weight to height ratio.

= OBESE

